GMR
The Original

LEGAL IMPLICATIONS OF AI IN HEALTHCARE: LIABILITY, ACCOUNTABILITY, AND ETHICS

Akhila Sawan[1], Dr. Dipak Anant Bauskar[2], Dr.Upasana Bharati[3]

[1]Research Scholar, Law, Criminal Law, Law College, Uttaranchal University, 248003, ORCID ID: 0009-0009-2293-8255, Email ID: akhilasawan@gmail.com
[2]Assistant Professor, Humanities and Sciences, Physics, Materials Science and Law, Email ID: dipak.bauskar@frcrce.ac.in, University of Mumbai, ORCID ID:0009-0007-2132-0117
[3]Professor, Department of English, Specialization in American literature, Applied Science & humanities, Major s.d.singh university , Uttar Pradesh, ORCID ID: 00 09000042904452, Email ID: upasanabajpai@rediffmail.com

ABSTRACT
The advent of artificial intelligence (AI) in healthcare has revolutionized the clinical decision making process by providing an opportunity to make data-driven therapeutic suggestions. This paper analyzes the trend in therapeutic recommendations based on structured healthcare data and discusses its consequences on the legal framework, such as liability, accountability, and ethical aspects. The relationships between clinical attributes, user generated reviews and demographic characteristics were analyzed through a descriptive analytical method involving use of a structured set of medical records between symptoms, conditions, and recommendations of drugs. The findings indicate that treatment prescriptions depend greatly on the various kinds of medical conditions and that there are a number of medications associated with similar clinical presentations, which is non-deterministic decision-making actions. The number of users rating and the number of reviewers are mostly distributed at higher scales implying the impact of evaluative traits on the pattern of recommendations. Demographic analysis indicates that there is variation between gender and age groups, and the constant availability of side-effect information emphasizes how tricky the choice of treatment is and the impact it has on patient safety. These observed trends bring on the problem of establishing legal responsibility since the variability and weak transparency make it difficult to attribute the liability and accountability in AI-assisted systems. The research highlights the importance of effective governance frameworks that can be used to deliver responsible, transparent, and ethically sound implementation of AI technologies in healthcare systems.

KEYWORDS: Artificial Intelligence in Healthcare; Therapeutic Recommendations; Liability; Accountability; Ethics; Clinical Decision Support Systems

1. INTRODUCTION

The use of artificial intelligence (AI) in the healthcare industry has significantly transformed the healthcare decision-making and patient treatment processes. Systems that are based on artificial intelligence (AI), including clinical decision support systems and recommendation engines, are increasingly used in assisting with diagnosis and treatment choice. The systems rely on the systematic medical information and are applied to the generation of therapeutic advice by establishing links between the symptoms, medical conditions and treatment options. The increased utilization of machine learning methods in medicine is a sign of change to a data-driven healthcare model, in which large amounts of clinical data are utilized to enhance the efficiency and accuracy of the decisions (Rajkomar et al., 2019; Yu et al., 2018).

Deep learning innovations have made AI systems capable of high performance in special clinical tasks. To give an example, AI models have proven to be similar to medical professionals when it comes to classifying diagnostic tasks like skin cancer detection (Esteva et al., 2017). The growing access to vast amounts of data and computing power has also contributed to the rapid growth of AI applications in healthcare, which underpins more sophisticated methods of analysis (Beam & Kohane, 2018). In this regard, the application of deep learning methods has been extensively investigated to derive meaningful patterns out of the intricate medical information, which opens up new opportunities and challenges to the healthcare systems (Miotto et al., 2018).

Although such technological innovations have been made, the practical application of AI in healthcare is still linked to a number of issues. Among the primary issues is that AI systems should provide meaningful clinical impact outside of the laboratory. To translate AIs models in real-life healthcare settings, it is necessary to tackle the problem of data quality, validation, and system reliability (Kelly et al., 2019). Also, predictive analytics applied to clinical medicine gives rise to uncertainties in decision-making because the outcomes can be different based on the structure and quality of data used as its foundation (Obermeyer and Emanuel, 2016). These issues underscore the need to institute governance mechanisms to inform the safe and efficient use of AI technologies (Reddy et al., 2020).

The other important area of AI integration into healthcare is the creation of clinical decision support systems. The use of more and more sophisticated datasets that assist healthcare professionals is supported by AI-based systems that provide them with recommendations (Shortliffe and Sepulveda, 2018). These systems can not only increase the accuracy of the diagnostic planning, treatment planning, but they also bring complexities about the interpretation and the user confidence. Interactions of such systems with clinical practice and personalized healthcare delivery should be considered in the

context of the real-life work with AI technologies (He et al., 2019). Moreover, the use of AI in specific fields, including medical imaging and cardiology, shows that it can be used to assist in more accurate and personalized diagnosis and treatment (Dilsizian and Siegel, 2014).

The growing use of AI systems also creates a problem of transparency and explainability of the decision-making processes. Most AI systems are run as black-box systems, in which the rationale behind outputs is not readily understandable (London, 2019). Such a lack of transparency may restrict the possibility of healthcare professionals to assess and trust the suggestions made by AI systems. Additionally, the introduction of AI into healthcare systems needs a knowledge of how these technologies will interplay with the larger health infrastructures and how they will affect system-level performance (Panch et al., 2018).

Besides technical and operational issues, the larger transformation of healthcare with the help of AI indicates the constant transformation of the process of generating and using medical knowledge. By facilitating novel types of data-driven analysis and decisions, AI technologies are becoming more and more influential in the contemporary healthcare system (Hamet & Tremblay, 2017). All of this is pointing to the necessity to look not at the performance of AI systems but also at the structures behind which healthcare information is structured and used.

Even though AI has proven to be a high potential in changing the nature of healthcare, it is necessary to deepen the insights into how the structure and organization of healthcare information affect therapeutic recommendations. A significant part of the current body of research has been devoted to technical abilities and performance of the system, and the impact of patterns in structured medical information on decision-making processes and results has received relatively little attention. This study will investigate the trends in therapeutic prescription in organized healthcare data and study the relationship between the trends and legal aspects, such as liability, accountability, and ethical aspects of AI-assisted health care systems.

2. METHODOLOGY

2.1 Research Design

This research is based on a descriptive analytical research design that will be used to conduct a systematic study of the trends in AI-based healthcare recommendations and the features of these recommendations. The design will aim to determine and describe observable relationships between clinical characteristics, therapeutic outcomes, user-performed ratings, and demographic. The approach does not emphasize predictive modeling or experimental procedures, but rather systematic analysis of existing medical data to study the organization and distribution of the various variables. Such design allows a thorough assessment of the patterns that are formed in the interaction of non-clinical and clinical characteristics.

2.2 Data Source

The research is grounded in a systematic dataset that includes medical conditions, symptoms and therapeutic recommendations (redflame03, n.d.). Each record contains a mix of clinical and contextual attributes, including the medical condition, related symptoms, prescribed medication, medication classification, reported side effects, user rating, the number of reviews, demographic attributes, including age group and gender, and the part of the body that is affected. These attributes are organized in a relational form with each record being a complete relationship between clinical input and therapeutic output alongside with the contextual information. This framework allows the analysis of several dimensions simultaneously within a certain analysis framework.

2.3 Data Preprocessing

Any duplicates and incomplete records were removed to achieve consistency and reliability.

2.4 Analytical Framework

The quantitative descriptive approach is utilized in the study to examine the trends in the recommendations of therapeutic options, user rating and demographic features. Derivation of summary measures, including counts, averages, and frequency distributions, was done through the use of aggregation and grouping techniques. The analysis involves the evaluation of the variation in therapeutic choices among medical conditions, classification of user ratings into specific ranges with specific measures of review, as well as the analysis of demographic representation among gender and age groups. The associations between symptoms, medical conditions, and therapeutic recommendations were also considered to learn how the attributes of each record were organised structurally.

3. RESULTS

3.1 Overview of Study Characteristics

The research investigates organized medical data between patient-reported symptoms and identified health conditions and therapeutic recommendations. The records will include several attributes like the drug classifications, the reported side effects, user rating, the number of reviews and demographic information like age group and gender. These attributes are always stored in every record creating a single representation where clinical variables are line by line with user-created and demographic data. This combined framework helps to identify the trends in treatment prescriptions, and their features.

3.2 Distribution of Therapeutic Options Across Conditions

The amount of therapeutic options that are related to every medical condition differs throughout the study. Table 1 encapsulates 48 medical conditions, each having an average of 8.3 drugs. The minimum number of drugs per condition is 1 with a maximum of 10 indicating variability in drug availability of treatment. There are 22 conditions with 9 or more drugs and a range of 1 to 10.

Table 1. Summary of therapeutic options across medical conditions

Metric	Value
Total Medical Conditions	48
Average Drugs per Condition	8.3
Maximum Drugs per Condition	10
Minimum Drugs per Condition	1
Conditions with ≥ 9 Drugs	22

To graphically depict this difference, Figure 1 shows the percentage contribution of each of the chosen medical conditions in relation to the number of therapeutic options associated with them.




Figure 1. Proportional distribution of therapeutic options among selected medical conditions

The figure demonstrates that some medical conditions represent a proportion of the therapeutic options, which is higher than others. The difference is a measure of the differences in medications associated with each condition in the study. The distribution also shows that there is no homogeneous distribution of therapeutic representation among all conditions.

3.3 Patterns in Therapeutic Recommendations

Similar clinical presentation has variability in therapeutic recommendations. There are several drugs that are linked with the similar symptom profile and medical conditions, which means that a recommendation is not confined to one therapeutic choice. This inconsistency is witnessed under various conditions in which various drugs can be found to have a relationship with similar clinical descriptions.

Moreover, treatment interventions encompass prescription drugs and over-the-counter drugs. These types are spread out over various conditions and this means that the recommendation does not exist in one type of classification. The existence of both types in the same clinical situations indicates the heterogeneity of treatment representation throughout the research.

3.4 Distribution of Ratings and Review Counts

Therapeutic recommendations are always linked with user ratings and the number of reviews. The frequency of these attributes is summarized in Table 2 that shows the number of entries and the mean number of reviews by various rating ranges. Most of the entries are focused in the higher rating range of 4-5 with 35 entries and average of 134.29 reviews whereas lower rating ranges have less entries.

Table 2. Distribution of ratings and associated review counts

Rating Range	Number of Entries	Mean Reviews
0 – 2	9	3.44
2 – 3	1	134.00
3 – 4	11	72.00
4 – 5	35	134.29

The distribution of the values of the ratings in general is depicted in Figure 2 that shows the frequency of the ratings amongst all entries.




Figure 2. Distribution of ratings across therapeutic recommendations

The histogram shows that more observations are in higher rating ranges. The range of lower ratings is represented by relatively fewer entries. The distribution indicates how the rating values are spread in various intervals within the study.

3.5 Representation of Side Effects

Side effects are always incorporated as a characteristic attached to every therapeutic suggestion. The research reveals that various medications that are related to the same health issue have different profile of side-effects. Each recommendation is accompanied by these profiles and is a descriptive part of the whole structure. The incorporation of side-effect data in all records indicates a cohesive choice of capturing features of treatments.

3.6 Demographic Distribution of Therapeutic Recommendations

Therapeutic suggestions are shared within demographic factors such as gender and age group. Table 3 provides the summary of the overall distribution showing the number of records in each demographic segment. The number of female entries is higher in all age categories and the most significant numbers of female entries are seen in female teenagers whereas the number of male entries is spread more widely across age groups.

Table 3. Distribution of records across gender and age groups

Category	Adult	Child	Teenager	Senior	Total
Male	31	35	34	36	136
Female	41	52	60	40	193
All	36	34	35	29	134

The age and gender distribution is also depicted by Figure 3 that shows a comparison of records by gender and age.




Figure 3. Distribution of records across gender and age groups

The figure indicates that the number of records varied among the various demographic categories. The female entries are more common among some age groups than others. The distribution also shows variation in the representation by age group of each group of gender.

3.7 Structural Relationships Among Clinical Attributes

The research has a coherent relational framework between symptoms, medical conditions, and treatment guidelines. Each record develops a relationship between the reported symptoms and a particular condition, and then a drug recommendation is given. Each record has other features like side effects, ratings, number of reviews and demographic signs.This organization makes sure that every attribute is interconnected in one representation.

These findings indicate that therapeutic recommendations differ in different medical conditions, and that various treatment options are related to various conditions. The ratings and the number of reviews are spread across entries, with more rating ranges concentrated in the higher rating ranges. Side effects are always added to every recommendation and demographic factors exhibit diversity in their representation by gender and age. Such patterns observed are all the characteristics of the therapeutic recommendations structure and distribution observed in the study.

4. DISCUSSION

The results of this paper illustrate the fact that the therapeutic prescription is marked with high variability in terms of different medical conditions, and there is a variety of drugs with specific symptom patterns. This inconsistency suggests that the use of healthcare recommendation systems based on structured medical information can produce various outputs given similar inputs in clinical settings. This non-deterministic nature indicates the intricacy of AI-assisted decision-making in healthcare since there might be various potential interventions to the same condition (Topol, 2019). Also, the effect of user-created ratings, like ratings and the number of reviews, points to the possibility of non-clinical characteristics affecting the patterns of recommendations, which raises the question of using such factors in the process of clinical decisions (Morley et al., 2020).

Legally, the inconsistency of the therapeutic recommendations is an issue that questions the conventional understanding of a standard of care. The liability in the traditional medical care setting is usually established on the grounds of whether a medical practitioner has acted contrary to the acceptable medical practice. Nonetheless, the existence of alternative treatments that qualify as an acceptable treatment makes it harder to determine negligence when AI systems provide a recommendation or otherwise (Gerke et al., 2020). This case brings uncertainty to determining what should be considered an appropriate decision, which makes the current liability frameworks, which are mostly fit to human decision-makers, problematic (Price & Cohen, 2019). Consequently, the responsibility can be spread beyond the healthcare providers and to the system developers and deploying institutions, which means that the liability models shift to distributed ones (Pham, 2025).

Responsibility is also enhanced by the unification of clinical and evaluative qualities to decision-making. The results show that recommendations are the result of a complex of structured clinical relationships, and user-generated inputs, which might not be transparently weighted or prioritized. Such a lack of transparency restricts the possibility of following the generation of particular decisions, thus undermining accountability mechanisms (Amann et al., 2020). In the healthcare setting, accountability is that the decisions made be explainable and justifiable; but due to the black-box characteristics of most AI systems, this is not possible (London, 2019). This limitation presents difficulties in attributing blame to the outcomes, especially in cases where mistakes or negative outcomes take place (Char et al., 2018).

The ethical considerations which arise out of the results also confront legal implications especially as far as fairness and equity are concerned. The difference in therapeutic advice given to the different demographic groups such as gender and age group indicates disparities in representation which can result into disproportionate results. These differences lead to an issue of bias and discrimination in AI-aided systems that can lead to legal implications when harm or inequality in access to care is caused (Vayena et al., 2018). The values of fairness and non-discrimination are believed to be the most important in the ethical framework, and it is necessary to ensure that AI systems do not lead to the already existing inequalities (Floridi et al., 2018).

Another important aspect of the interconnection of ethics and legal responsibility is patient safety. The analysis reveals that various medications that are related to the same condition have varying side-effect profiles, which means that the safety implication varies. Legally, the inability to properly consider such distinctions can lead to stakeholders being liable, especially in case AI-aided recommendations lead to preventable harm (Grote and Berens, 2020). It is therefore important to ensure that safety related attributes are systematically incorporated in the decision making processes to ensure that ethical obligations as well as legal requirements are met.

Transparency has been one of the main concerns in the creation of accountability and legal responsibility. The design of the attributes in the study shows that there are several factors to be considered in the therapeutic recommendations; nevertheless, no explicit prioritization of the attributes identifies the lack of interpretability. Transparency is critical in legal matters to assess decision channels and determine evidence in a dispute situation (World Health Organization, 2021). This lack of explainability which can be seen in AI systems can potentially impede the capacity to distribute responsibility and enforce accountability, which has implications on trust and adoption in a healthcare context (Pasricha, 2022).

The result also indicates the influence of structured healthcare information on influencing the outcome of a decision. The connection between symptoms, conditions, and treatment, as well as with the evaluative and demographic characteristics, can prove that the underlying data structures determine the recommendations. The differences in the representation and use of these attributes can result in inconsistencies in outputs, which can cause issues related to reliability and standardization (Khan et al., 2022). These inconsistencies complicate the development of consistent standards of system performance, because they are legally challenging.

The results underscore the significance of the creating regulatory and control frameworks that would address the complexities of AI-based healthcare systems. Accountability, transparency, and fairness in system design and deployment are highlighted in ethical and legal guidelines (Hagendorff, 2019). The inconsistency of the patterns of recommendations witnessed shows that the existing regulation methods may need to accommodate the reality of distributed decision-making and shared responsibility (Gorelik et al., 2025). This involves risk assessment system development, system audits and sharing of the responsibilities of the stakeholders.

This paper indicates that clinical, evaluative and demographic features are confounded to influence the therapeutic recommendations that is variable under short term legal and ethical consequences. This ambiguity undermines the classical theory of liability and complicates the process of accountability, and raises the question of fairness, safety, and transparency. Its results highlight the importance of creating legally educated, transparent and ethical frameworks in order to ensure the responsible integration of AI technologies in the healthcare systems could be realized.

5. CONCLUSION

The paper has described the trends in prescriptions and therapies within the context of systematized healthcare data and provided the overview of its legal and ethical character of AI-assisted decision-making. The results indicate that the treatment prescriptions vary widely among different medical conditions and that there are high treatment options that are ascribed to the same clinical inputs. This variability is the non-determinism of AI-assisted systems and emphasizes the sophistication of the patterns of decision-making that rely on clinical and non-clinical factors, such as user judgement and demography. This research also indicates that this volatility presents difficulties in the formulation of unambiguous standards on liability and accountability. The absence of a single treatment plan makes the issue of responsibility in the cases of bad outcome, particularly in cases of using AI systems, rather problematic. The issue of transparency and interpretability also arises when different features are introduced to the decision-making processes to ensure that healthcare applications are reliable and trustworthy. The results illustrate the need to establish proper governance systems and regulatory frameworks to train the use of AI in the healthcare industry. The research contributes to the comprehension of how structured healthcare information influences AI-assisted recommendations and the necessity to be responsible, transparent, and accountable in the utilization of AI technologies in clinical practice.

REFERENCES

1. Amann, J., Blasimme, A., Vayena, E., Frey, D., Madai, V. I., & Precise4Q Consortium. (2020). Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC medical informatics and decision making, 20(1), 310.
2. Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. Jama, 319(13), 1317-1318.
3. Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care—addressing ethical challenges. The New England journal of medicine, 378(11), 981.
4. Dilsizian, S. E., & Siegel, E. L. (2014). Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment. Current cardiology reports, 16(1), 441.
5. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. nature, 542(7639), 115-118.
6. Floridi, L., Cowls, J., Beltrametti, M., Chatila, R., Chazerand, P., Dignum, V., ... & Vayena, E. (2018). AI4People—An ethical framework for a good AI society: Opportunities, risks, principles, and recommendations. Minds and machines, 28(4), 689-707.
7. Gerke, S., Minssen, T., & Cohen, G. (2020). Ethical and legal challenges of artificial intelligence-driven healthcare. In Artificial intelligence in healthcare (pp. 295-336). Academic Press.
8. Gorelik, A. J., Li, M., Hahne, J., Wang, J., Ren, Y., Yang, L., ... & Carpenter, B. D. (2025). Ethics of AI in healthcare: a scoping review demonstrating applicability of a foundational framework. Frontiers in Digital Health, 7, 1662642.
9. Grote, T., & Berens, P. (2020). On the ethics of algorithmic decision-making in healthcare. Journal of medical ethics, 46(3), 205-211.
10. Guidance, W. H. O. (2021). Ethics and governance of artificial intelligence for health. World Health Organization, 1-165.
11. Hagendorff, T. (2019). The ethics of AI ethics--an evaluation of guidelines. arXiv preprint arXiv:1903.03425.
12. Hamet, P., & Tremblay, J. (2017). Artificial intelligence in medicine. metabolism, 69, S36-S40.
13. He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019). The practical implementation of artificial intelligence technologies in medicine. Nature medicine, 25(1), 30-36.
14. Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC medicine, 17(1), 195.
15. Khan, A. A., Badshah, S., Liang, P., Waseem, M., Khan, B., Ahmad, A., ... & Akbar, M. A. (2022, June). Ethics of AI: A systematic literature review of principles and challenges. In Proceedings of the 26th international conference on evaluation and assessment in software engineering (pp. 383-392).
16. London, A. J. (2019). Artificial intelligence and black-box medical decisions: accuracy versus explainability. Hastings Center Report, 49(1), 15-21.
17. London, A. J. (2019). Artificial intelligence and black-box medical decisions: accuracy versus explainability. Hastings Center Report, 49(1), 15-21.
18. Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: review, opportunities and challenges. Briefings in bioinformatics, 19(6), 1236-1246.

19. Morley, J., Machado, C. C., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2020). The ethics of AI in health care: a mapping review. Social science & medicine, 260, 113172.
20. Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future—big data, machine learning, and clinical medicine. The New England journal of medicine, 375(13), 1216.
21. Panch, T., Szolovits, P., & Atun, R. (2018). Artificial intelligence, machine learning and health systems. Journal of global health, 8(2), 020303.
22. Pasricha, S. (2022). AI ethics in smart healthcare. IEEE Consumer Electronics Magazine, 12(4), 12-20.
23. Pham, T. (2025). Ethical and legal considerations in healthcare AI: innovation and policy for safe and fair use. Royal Society Open Science, 12(5).
24. Price, W. N., & Cohen, I. G. (2019). Privacy in the age of medical big data. Nature medicine, 25(1), 37-43.
25. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347-1358.
26. Reddy, S., Allan, S., Coghlan, S., & Cooper, P. (2020). A governance model for the application of AI in health care. Journal of the American medical informatics association, 27(3), 491-497.
27. redflame03. (n.d.). Medical chatbot dataset (Gen AI) [Data set]. Kaggle. https://www.kaggle.com/datasets/redflame03/medical-chatbot-dataset-gen-ai
28. Shortliffe, E. H., & Sepúlveda, M. J. (2018). Clinical decision support in the era of artificial intelligence. Jama, 320(21), 2199-2200.
29. Topol, E. (2019). Deep medicine: how artificial intelligence can make healthcare human again. Hachette UK.
30. Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine learning in medicine: addressing ethical challenges. PLoS medicine, 15(11), e1002689.
31. Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. Nature biomedical engineering, 2(10), 719-731.